Today Stories

Research & Development (R&D) jobs are the most in-demand across the Life Sciences sector with vacancies up 5% year-on-year. That’s according to new research from the Association of Professional Staffing Companies (APSCo), the trade association for the professional staffing sector. According to the data, provided by business intelligence specialist Vacancysoft, R&D jobs across the UK are predicted to reach 4,218 by the end of 2022 and now account for 34% of jobs posted within the Life Sciences arena. When analysing the data by region, it’s perhaps no surprise that the biggest concentration of jobs was noted across the South East, with vacancies hitting over 3,000 year-to-date. By contrast, the research reveals that Yorkshire and the Humber could see the most considerable decreas…

Partnership between the University of Birmingham and Acticor Biotech will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time. A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. The randomised, double-blind Phase 2b LIBERATE study will recruit more than 200 patients to test the tolerance and the efficacy of glenzocimab 1000 mg, versus placebo, to reduce heart damage following a myocardial infarction (MI), commonl…

Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply our global clinical trials. These expansions will provide capacity for developing Novo Nordisk’s future oral and injectable product portfolio. “This investment in expanding our clinical API capacity in Bagsværd is an important step to ensure the continuous progress of our development pipeline. Increasing our API capacity in R&D will be a key enabler in bringing new innovations to the market, and meet…

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion. “We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve,” said Robert M. Davis, president and chief executive officer, Merck. “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology.” Imago is a clinical stage biopharmaceutical com…

EDX Medical Group plc, (“EDX Medical” or the “Company”), which develops innovative digital diagnostic products and services for cancer, heart disease, neurology and infectious disease testing, today announces a collaborative cancer biomarker programme that will improve access to cost-effective and reliable tests for a range of cancers in the UK and Europe. The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd (“Bioscience”), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe. The programme will encompass the v…

World antibiotic awareness week 18 to 25 November 2022 In 2019, it was estimated that 1.2 million deaths globally, were due to antibiotic-resistant infections1. In England, during 2019/20, there were over 90,000 hospital admissions2 – yet the global pipeline for new antibiotics to address this growing problem has been failing. This year’s World Antimicrobial Awareness Week aims to improve the awareness and understanding of antimicrobial resistance (AMR). The event seeks to encourage best practices among the public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance. We are now living in an age where drug resistant microbes are developing faster than new antimicrobial treatments, which poses a huge threat to modern medicine. Amit Aggarwal, Ex…

London, U.K., 17 November 2022: Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research. Velocity is the first US-based clinical research sites business to expand into Europe, bringing its total number of dedicated research locations to 42. The addition of Egin Research’s two sites increases Velocity’s European site footprint to three, after its first European purchase in Hamburg, Germany in July 2022 and further growth expected over the next 12 months. Dominic Clavell, Executive Vice President, Europe, said, “The size and importance of the UK market for clinical research cannot be underestimated. There is a focus on clinical trial regulation reform in a…

Company also announces £100 million investment over next ten years to support health system strengthening and access initiatives in lower income countries GSK ranks 1st in the 2022 Access to Medicine Index (ATMI) report published today. The Index is an independent, investor-backed report that ranks 20 of the world’s largest pharmaceutical companies on progress to improve access in 108 lower income countries and focuses on 83 high burden priority diseases. Emma Walmsley, Chief Executive Officer, GSK, said: “We are delighted to have ranked first in the Access to Medicine Index (ATMI) for the eighth consecutive time. This is recognition of the action we are taking to get ahead of disease together and improve access to medicine and vaccines in lower income countries, and I want to thank all of…

Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe Secured exclusive rights in 26 European Countries to an investigational orphan medicine for the treatment of an ultra-rare ophthalmologic disease, currently under review by the European Medicines Agency for marketing approval Founded by biopharmaceutical executives Adam Plich, CEO, and Anant Murthy, Board Advisor, with the backing of a seasoned Advisory Board AMSTERDAM--(BUSINESS WIRE)--Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical orig…

Los Angeles, California, USA, November 15, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, non-exclusive license agreement with DynamiCure Biotechnology, a private biopharmaceutical company developing innovative therapeutic antibody candidates to treat cancer, autoimmune disorders, and other diseases.  Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETTM to DynamiCure Biotechnology for use in its clinical trial. Commenting on the announcement, Ian Wilson, CEO of ImaginAb, said: “We are delighted that DynamiCure Biotechnology will be using our CD8 ImmunoPET…

Positive opinion based on TOPAZ-1 Phase III trial updated survival results showing Imfinzi combination reduced risk of death by 24% vs. chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on the primary results from the TOPAZ-1 Phase III trial published in the New England Journal of Medicine Evidence, and on the updated results presented at the European Society for Medical Oncology Congress 2022. At the interim analysis, Imfinz…

Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix will continue its start-up approach as a standalone entity wholly-owned by Bayer  Monheim, November 10, 2022 – Bayer announced today the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) uses novel systems biology and computational life science tools to identify new modes of action for crop protection compounds. The Targenomix expertise, personnel, and platforms will be an important part of delivering on Bayer’s commitment to the design of sa…

Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds NRG is developing inhibitors of a first-in-class target as a potential disease-modifying treatment for Parkinson's and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) towards the clinic The financing enables UK-headquartered NRG Therapeutics to expand its research team in Australia led by Prof Seth Masters under an agreement with WEHI (Walter and Eliza Hall Institute of Medical Research) Jonathan Tobin, Partner at Brandon Capital, joins the NRG board; and Prof Masters joins the management team as VP Discovery Biology Melbourne, Australia and London UK, 9 November 2022 – Brandon Capital, Australasia’s leading life science venture capital firm…

Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through platform interface may help healthcare providers make data-driven decisions± about care for adults treated with select Lilly insulins Offers compatibility with the Dexcom® Continuous Glucose Monitoring Systems, *,∞ the Tempo Blood Glucose Monitor (BGM) and other compatible BGMs, as well as wearable devices from Fitbit®, Garmin®, Google Fit® and the Apple Health app INDIANAPOLIS, Nov. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 dia…

Singleron Biotechnologies, a leader in single cell multi-omics analysis, is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications. Through customer demonstrations, these modern laboratories will provide potential customers a hands-on approach allowing the opportunity to test the latest developments Singleron has to offer in single cell sequencing. The laboratories will also augment Singleron’s productivity to extend operations in research and development of novel products to further Singleron’s innovative technology portfolio. The new state of the art laboratory will complement the already established single cell…

Educators and school officials encouraged to drive student awareness of state and regional science fairs for a chance to enter nation’s premier middle school STEM competition WALTHAM, Mass. & WASHINGTON--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Society for Science (the Society), today announced the Thermo Fisher Scientific Junior Innovators Challenge, the nation’s premier middle school science, technology, engineering and math (STEM) competition. The Society named Thermo Fisher as the new title sponsor of the organization’s middle school STEM competition in August. “Society for Science is very excited to embark on this new partnership with Thermo Fisher Scientific,” said Maya Ajmera, President and CEO of Society for Science a…

LEIDEN, The Netherlands, November 02, 2022 / B3C newswire / -- MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position. Henk Volberda, chairman of the jury and professor of Strategy & Innovation at the University of Amsterdam: “MIMETAS is world-leading. Since its foundation in 2013, the company has grown considerably, with branches in Europe, the USA, and Asia. It can now count the largest pharmaceutical companies worldwide among its partners. With its miniaturized organs-on-a-chip, MIMETAS has found a promising approach to enable major advancements in the pharmaceutical industry.” “The…

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart RecoveryTransaction to Bring Lifesaving Innovations to More Patients with Unmet NeedExpected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction New Brunswick, N.J. and Danvers, Mass., November 1, 2022 – Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender o…

– Leaders in biotech and genomics to launch more personalised genomic solutions to more than 10,000 people across the Baltics and Mediterranean regions – L’AQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Biotechnology startup Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants. WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, servic…

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates. Serving clinicians and laboratory pro…